University of Colorado Hospital CRS

Location	Colorado ACTU, Academic Office 1, MS 8205, P.O. Box 6511, 12631 East 17th Avenue Aurora, CO 80045 United States of America
Phone	303-372-5535
CRS Coordinator	Suzanne Fiorillo suzanne.fiorillo@ucdenver.edu 303-724-5931
CRS Leader	Thomas Campbell thomas.campbell@ucdenver.edu 303-724-4929
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5345: HIV Rebound & Control Biomarkers A5354: Early ART in Acute HIV A5359: The LATITUDE Study A5370: Anti-PD-1 Antibody in HIV-1 A5375: Optimize LNG EC A5377: Tri-specific Antibody A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study)